Showing results (221-230 of 679) with videos related to

Sort By:
Pageof 68
Blood Cancer Journal|March 22, 2022
Extramedullary disease in multiple myeloma: a systematic literature reviewJoan Bladé, Meral Beksac, Jo Caers, et al.
Transplantation|November 5, 2016
Impact of Graft-Versus-Graft Natural Killer Cell Alloreactivity on Single Unit Dominance After Double Umbilical Cord Blood TransplantationPauline Rettman, Catherine Willem, Christelle Volteau, et al.
Hematological Oncology|February 25, 2024
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA studyThierry Facon, Philippe Moreau, Ivan Špicka, et al.
Expert Review of Hematology|September 23, 2021
Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategiesKamlesh Bisht, Brian Walker, Shaji K Kumar, et al.
Blood|October 13, 2018
BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatmentPatricia Gomez-Bougie, Sophie Maiga, Benoît Tessoulin, et al.
Malaria Journal|August 14, 2014
High plasma levels of HLA-G are associated with low birth weight and with an increased risk of malaria in infancyIbrahim Sadissou, Tania d'Almeida, Gilles Cottrell, et al.
Blood Cells, Molecules & Diseases|February 21, 2012
Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cellsDavid Chiron, Sophie Maïga, Géraldine Descamps, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2012
Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosisEtienne Crickx, Sebastian Wittnebel, Florence Pasquier, et al.
Molecular Immunology|February 21, 2015
MicroRNAs targeting the immunomodulatory HLA-G gene: a new survey searching for microRNAs with potential to regulate HLA-GIane O P Porto, Celso T Mendes-Junior, Leandro P Felício, et al.
Leukemia Research|April 16, 2013
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myelomaPaul G Richardson, Constantine S Mitsiades, Jacob P Laubach, et al.
Pageof 68